Article
The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies.
International journal of molecular sciences - 14 Mar 2021
Stege Nienke M, de Boer Rudolf A, van den Berg Maarten P, Silljé Herman H W
Abstract excerpt
For patients with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM), screening for pathogenic variants has become standard clinical practice. Genetic cascade screening also allows the identification of relatives that carry the same mutation as the proband, but disease onset and severity in mutation carriers often remains uncertain. Early detection of disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.